Read on Twitter
$AFMD is up 70% vs. one year ago vs. 50% for $XBI. Modest outperformance. Here's what's changed in the last year:
1) AFM13 registrational trial in CD30+ PTCL trial WAS initiating, NOW sufficiently enrolled for interim data in 1H21.
1) AFM13 registrational trial in CD30+ PTCL trial WAS initiating, NOW sufficiently enrolled for interim data in 1H21.
2) AFM13 + NK cells collab with MD Anderson WAS taking forever, no one knew when it'd go, NOW first patient dosed, PR after one month.
3) AFM24 EGFR IND WAS just cleared, NOW enrolling dose cohort 3, where responses may begin to emerge.
3) AFM24 EGFR IND WAS just cleared, NOW enrolling dose cohort 3, where responses may begin to emerge.
4) AFM26 aka R07297089, the Genentech partnered BCMA asset WAS pre IND, now ph1 initiated in 3Q20.
5) This week $60m upfront from Roivant for preclinical assets extended cash runway into 1H23.
6) NK space has heated up thanks to $FATE and others.
5) This week $60m upfront from Roivant for preclinical assets extended cash runway into 1H23.
6) NK space has heated up thanks to $FATE and others.
Anyhow, looks to me like $AFMD is finally executing in the clinic. I began adding yesterday. Spec bet. But the knock here has always been "mgmt can't execute". Looks to me like that's changing.
